Merck Shares Slide 1.73% on Tumour Trial Delays, Volume Ranks 139th as Diabetes Sales Offset

Merck (MRK) fell 1.73% with a trading volume of $0.97 billion, ranking 139th in market activity on October 10, 2025. The decline followed a mixed earnings report highlighting delays in key clinical trials for its oncology pipeline, though robust sales of its diabetes drug Januvia partially offset near-term concerns about R&D timelines.

Analysts noted that the stock's performance remained sensitive to macroeconomic factors, as rising bond yields pressured growth-oriented sectors. While Merck's core pharmaceutical business showed resilience, investors remained cautious about its ability to meet 2026 revenue guidance without accelerating high-cost acquisitions or regulatory approvals.

To back-test the idea rigorously we need two additional pieces of information the system doesn’t currently have: (1) A daily file (or API) listing the 500 highest-volume stocks per trading day; (2) A definition of trade execution parameters—whether to buy at next day’s open/sell same day’s close or buy/sell at close-to-close. Without these, valid daily buy-lists cannot be constructed. If the S&P 500 constituents are used as a proxy, the strategy fundamentally changes. Please specify preferred execution timing and provide the required data to proceed.